Ibalizumab

from Wikipedia, the free encyclopedia
quality control This article was based on formal and / or substantive defects on the quality assurance side of the editorial Medicine entered. Please help fix the shortcomings in this article and join the discussion there . The minimum requirements for medical articles are to be met, thereby avoiding a possible deletion of the article or article passages within four weeks.
Medical editors
Ibalizumab
other names
  • Trogarzo
  • ibalizumab-uiyk
  • TMB-355
  • TNX-355
Identifier
External IDs
Drug information
DrugBank DB12698
Drug class Monoclonal antibody

Ibalizumab is the first humanized monoclonal antibody for the treatment of HIV infection . Ibalizumab was approved by the FDA in 2018 .

Working principle

Ibalizumab blocks the CD4 receptor .

Indications

Treatment of multidrug-resistant HIV-1 infection in combination with other antiretroviral drugs.

Contraindications

Hypersensitivity .

Individual evidence

  1. ^ Novel Drug Approvals for 2018 . FDA .
  2. Anthony Markham: Ibalizumab: First Global Approval . In: Drugs . tape 78 , no. 7 , May 2018, p. 781 , doi : 10.1007 / s40265-018-0907-5 , PMID 29675744 .
  3. TROGARZO- Ibalizumab injection, solution . DailyMed .